Abstract
Clinically, deregulation of PTEN function resulting in reduced PTEN expression and/or activity is implicated in human disease. Cowden syndrome (CS) is an autosomal dominant disorder characterized by benign and malignant tumors. CS-related individual features occur commonly in the general population. Approximately 25 % of patients diagnosed with CS have pathogenic germline PTEN mutations, which increase lifetime risks of breast, thyroid, uterine, renal, and other cancers. PTEN testing and intensive cancer surveillance allow for early detection and treatment of these cancers for mutation-positive patients and their relatives. In this methods chapter, we highlight our protocol for identifying patients at risk of harboring a germline PTEN mutation.
Original language | English |
---|---|
Title of host publication | Methods in Molecular Biology |
Publisher | Humana Press Inc. |
Pages | 63-73 |
Number of pages | 11 |
DOIs | |
Publication status | Published - 2016 |
Externally published | Yes |
Publication series
Name | Methods in Molecular Biology |
---|---|
Volume | 1388 |
ISSN (Print) | 1064-3745 |
Bibliographical note
Publisher Copyright:© Springer Science+Business Media New York 2016.
ASJC Scopus Subject Areas
- Molecular Biology
- Genetics
Keywords
- Cancer
- PTEN hamartoma tumor syndrome